PMID- 35165593
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220216
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 14
IP  - 1
DP  - 2022 Jan
TI  - Elevated Plasma Levels of CXCL13 Chemokine in Saudi Patients With Asthma 
      Exacerbation.
PG  - e21142
LID - 10.7759/cureus.21142 [doi]
LID - e21142
AB  - BACKGROUND:  Bronchial asthma is a lung disorder characterized by chronic 
      allergic inflammation of the airways, and several of the immune and non-immune 
      cells contribute to asthma's pathogenicity. B-cell activation plays an essential 
      role in developing allergic inflammation in the lungs. CXCL13 is a potent B-cell 
      chemoattractant chemokine, which has a crucial role in the recruitment and 
      trafficking of B cells after interaction with its receptor CXCR5. This study is 
      aimed to evaluate plasma levels of CXCL13 and its receptor CXCR5 in Saudi 
      patients with asthma exacerbation relative to healthy controls. METHODS:  A total 
      of 23 patients with asthma exacerbation and 20 healthy controls participated in 
      this study. Total immunoglobulin E (IgE) and CXCL13 protein levels were measured 
      in the plasma of patients with asthma exacerbations and healthy controls by 
      specific enzyme-linked immunosorbent assay (ELISA). Gene expression mRNA for 
      CXCR5 was measured using real-time polymerase chain reaction (RT-PCR). RESULTS: 
       Total IgE protein concentrations were elevated significantly in asthma 
      exacerbation patients than that in healthy controls. CXCL13 protein levels were 
      increased significantly in the asthma group relative to healthy controls. In 
      addition, CXCR5 mRNA levels were elevated significantly in the asthma group than 
      in the healthy controls. CONCLUSIONS:  Measurement of CXCL13 and CXCR5 may be 
      used as an additional biomarker of asthma exacerbation, and targeting CXCL13 or 
      its receptor may be used as new treatment options in asthma.
CI  - Copyright (c) 2022, Alturaiki et al.
FAU - Alturaiki, Wael
AU  - Alturaiki W
AD  - Department of Medical Laboratory Sciences, College of Applied Medical Sciences, 
      Majmaah University, Majmaah, SAU.
LA  - eng
PT  - Journal Article
DEP - 20220112
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC8832178
OTO - NOTNLM
OT  - asthma
OT  - b cells
OT  - cxcl13
OT  - cxcr5
OT  - total ige
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/02/16 06:00
MHDA- 2022/02/16 06:01
PMCR- 2022/01/12
CRDT- 2022/02/15 05:36
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/02/15 05:36 [entrez]
PHST- 2022/02/16 06:00 [pubmed]
PHST- 2022/02/16 06:01 [medline]
PHST- 2022/01/12 00:00 [pmc-release]
AID - 10.7759/cureus.21142 [doi]
PST - epublish
SO  - Cureus. 2022 Jan 12;14(1):e21142. doi: 10.7759/cureus.21142. eCollection 2022 
      Jan.